Citius Oncology (CTOR) Stock Price, News & Analysis

Company Overview

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Key Stats

• Today's Range: $1.83 to $2.00
• 50-Day Range: $1.48 to $2.21
• 52-Week Range: $0.55 to $6.19
• Volume: 286,050 shs
• Average Volume: 192,963 shs
• Market Capitalization: $156.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Citius Oncology Stock Analysis - MarketRank™

Citius Oncology scored higher than 49% of companies evaluated by MarketBeat, and ranked 599th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Citius Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Citius Oncology has a consensus price target of $6.00, representing about 200.0% upside from its current price of $2.00.

Amount of Analyst Coverage

Citius Oncology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Citius Oncology has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.94% of the float of Citius Oncology has been sold short.

Short Interest Ratio / Days to Cover

Citius Oncology has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Citius Oncology does not currently pay a dividend.

Dividend Growth

Citius Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.94% of the float of Citius Oncology has been sold short.

Short Interest Ratio / Days to Cover

Citius Oncology has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.56

News Sentiment

Citius Oncology has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Citius Oncology this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for CTOR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Citius Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.57% of the stock of Citius Oncology is held by insiders.

Percentage Held by Institutions

70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTOR Stock Analysis - Frequently Asked Questions

How have CTOR shares performed this year?

Citius Oncology's stock was trading at $1.15 at the start of the year. Since then, CTOR stock has increased by 73.9% and is now trading at $2.00.

How were Citius Oncology's earnings last quarter?

Citius Oncology, Inc. (NASDAQ:CTOR) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02.

Who are Citius Oncology's major shareholders?

Top institutional investors of Citius Oncology include Jane Street Group LLC (0.14%), Geode Capital Management LLC (0.07%), Arkadios Wealth Advisors (0.01%) and Bank of America Corp DE (0.01%).

How do I buy shares of Citius Oncology?

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Citius Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 9/26/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTOR
• Previous Symbol: NASDAQ:CTOR
• CIK: 1851484
• Web: www.citiusonc.com
• Phone: 347-627-0058
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Citius Oncology: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +200.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.93%
• Return on Assets: -22.17%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 0.35
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 78,370,000
• Free Float: 74,789,000
• Market Cap: $156.74 million
• Optionable: N/A
• Beta: 2.99